StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Credit Suisse Sees Up to a $7 Cut in Target Price to Clovis (CLVS) if Platinum Resistant/Refractory Removed; M&A Thesis Intact
October 7, 2016 1:20 PM
Credit Suisse analyst Kennen MacKay reiterated an Outperform rating and $41 price target on Clovis Oncology (NASDAQ: CLVS) after the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Rumors
Next Articles
Clovis (CLVS): Solid Treatment Choice but Maintenance Use Seems Unlikely - Stifel
October 7, 2016 11:16 AM
Clovis Oncology (CLVS) Defended at SunTrust
October 7, 2016 10:56 AM
Clovis Oncology (CLVS) Bounces Off Lows, Remains Down 13.8%
October 7, 2016 10:44 AM
Clovis Oncology (CLVS) Announces Presentation of Encouraging Efficacy, Safety Data on Rucaparib in BRCA Ovarian Cancer
October 7, 2016 8:46 AM
Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress
October 7, 2016 8:45 AM
